TESARO Inc TSRO shares are trading higher by $0.33 at $140.00 in Friday's session.
The stock fell out of bed around 10:00 a.m. ET, when Johnson & Johnson JNJ suspended enrollment of Tesaro's Niraparib Phase 2 prostrate cancer trial pending review of data collected.
In a matter of 16 minutes, Tesaro's stock swooned from the $139.00 area all the way to $125.05 before staging a dramatic rebound. The stock was struggling to recover until 11:00 a.m. when Wells Fargo came out and defended the issue.
At this time, the rebound off the low took Tesaro's stock within a few pennies of the session high ($140.74) but retreated to the $140.00 area.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.